Page 42 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 42
severe asthma registries. Eur Respir Am J Respir Crit Care Med. 2021 Apr
J. 2020 Jan 9;55(1):1901163. doi: 1;203(7):795-6.
severe asthma forum 1: severe asthma - basic and clinical views 10.1183/13993003.01163-2019. 21. Suehs CM, Menzies-Gow A, Price D, et
12. Maijers I, Kearns N, Harper J, et al. al. Oral Corticosteroids Tapering Del-
Oral steroid-sparing effect of high-dose phi Expert Panel. Expert consensus on
inhaled corticosteroids in asthma. Eur- the tapering of oral corticosteroids for
Respir J. 2020 Jan 2;55(1):1901147. doi: the treatment of asthma: a Delphi study.
10.1183/13993003.01147-2019. Am J Respir Crit Care Med. 2021 Apr
13. Masoli M, Weatherall M, Holt S, et al. 1;203(7):871-81.
Inhaled fluticasone propionate and ad- 22. Mortimer KJ, Tata LJ, Smith CJ, et al.
renal effects in adult asthma: systematic Oral and inhaled corticosteroids and
review and meta-analysis. Eur Respir J. adrenal insufficiency: a case-control
2006 Nov;28(5):960-7. study. Thorax. 2006 May;61(5):405-8.
14. Aaronson D, Kaiser H, Dockhorn R, 23. Prete A, Bancos I. Glucocorticoid in-
et al. Effects of budesonide by means of duced adrenal insufficiency. BMJ. 2021
the Turbuhaler on the hypothalmic-pi- Jul 12;374:n1380. doi: 10.1136/bmj.
tuitary-adrenal axis in asthmatic sub- n1380.
jects: a dose-response study. J Allergy 24. Menzies-Gow A, Gurnell M, Heaney
Clin Immunol. 1998 Mar;101(3):312-9. LG, et al. Oral corticosteroid elimina-
15. Bourdin A, Suehs C, Charriot J. Inte- tion via a personalised reduction algo-
grating high dose inhaled corticosteroids rithm in adults with severe, eosinophilic
into oral corticosteroids stewardship. asthma treated with benralizumab (PO-
Eur Respir J. 2020 Jan 2;55(1):1902193. NENTE): a multicentre, open-label,
doi: 10.1183/13993003.02193-2019. single-arm study. Lancet Respir Med.
16. Braunstahl GJ, Chlumský J, Peachey 2021 Jan;10(1):47-58.
G, et al. Reduction in oral corticoster- 25. Iqbal K, Halsby K, Murray RD, et al.
oid use in patients receiving omalizum- Glucocorticoid management of adrenal
ab for allergicasthma in the real-world insufficiency in the United Kingdom:
setting. Allergy Asthma Clin Immunol. assessment using real-world data. Endo-
2013;9(1):47. doi: 10.1186/1710-1492-9- cr Connect. 2019;8(1):20-31.
47.
17. Bel EH, Wenzel SE, Thompson PJ, et
al. Oral glucocorticoid-sparing effect of
mepolizumab in eosinophilic asthma. N
Engl J Med. 2014 Sep 25;371(13):1189-
97.
18. Nair P, Wenzel S, Rabe KF, et al. Oral
glucocorticoid-sparing effect of benrali-
zumab in severe asthma. N Engl J Med.
2017 Jun 22;376(25):2448-58.
19. Rabe KF, Nair P, Brusselle G, et al. Ef-
ficacy and safety of dupilumab in glu-
cocorticoid-dependent severe asthma. N
Engl J Med. 2018 Jun 28;378(26):2475-
85.
20. Boulet L-P, Godbout K. Oral corti-
costeroids tapering in severe asthma.
J. 2020 Jan 9;55(1):1901163. doi: 1;203(7):795-6.
severe asthma forum 1: severe asthma - basic and clinical views 10.1183/13993003.01163-2019. 21. Suehs CM, Menzies-Gow A, Price D, et
12. Maijers I, Kearns N, Harper J, et al. al. Oral Corticosteroids Tapering Del-
Oral steroid-sparing effect of high-dose phi Expert Panel. Expert consensus on
inhaled corticosteroids in asthma. Eur- the tapering of oral corticosteroids for
Respir J. 2020 Jan 2;55(1):1901147. doi: the treatment of asthma: a Delphi study.
10.1183/13993003.01147-2019. Am J Respir Crit Care Med. 2021 Apr
13. Masoli M, Weatherall M, Holt S, et al. 1;203(7):871-81.
Inhaled fluticasone propionate and ad- 22. Mortimer KJ, Tata LJ, Smith CJ, et al.
renal effects in adult asthma: systematic Oral and inhaled corticosteroids and
review and meta-analysis. Eur Respir J. adrenal insufficiency: a case-control
2006 Nov;28(5):960-7. study. Thorax. 2006 May;61(5):405-8.
14. Aaronson D, Kaiser H, Dockhorn R, 23. Prete A, Bancos I. Glucocorticoid in-
et al. Effects of budesonide by means of duced adrenal insufficiency. BMJ. 2021
the Turbuhaler on the hypothalmic-pi- Jul 12;374:n1380. doi: 10.1136/bmj.
tuitary-adrenal axis in asthmatic sub- n1380.
jects: a dose-response study. J Allergy 24. Menzies-Gow A, Gurnell M, Heaney
Clin Immunol. 1998 Mar;101(3):312-9. LG, et al. Oral corticosteroid elimina-
15. Bourdin A, Suehs C, Charriot J. Inte- tion via a personalised reduction algo-
grating high dose inhaled corticosteroids rithm in adults with severe, eosinophilic
into oral corticosteroids stewardship. asthma treated with benralizumab (PO-
Eur Respir J. 2020 Jan 2;55(1):1902193. NENTE): a multicentre, open-label,
doi: 10.1183/13993003.02193-2019. single-arm study. Lancet Respir Med.
16. Braunstahl GJ, Chlumský J, Peachey 2021 Jan;10(1):47-58.
G, et al. Reduction in oral corticoster- 25. Iqbal K, Halsby K, Murray RD, et al.
oid use in patients receiving omalizum- Glucocorticoid management of adrenal
ab for allergicasthma in the real-world insufficiency in the United Kingdom:
setting. Allergy Asthma Clin Immunol. assessment using real-world data. Endo-
2013;9(1):47. doi: 10.1186/1710-1492-9- cr Connect. 2019;8(1):20-31.
47.
17. Bel EH, Wenzel SE, Thompson PJ, et
al. Oral glucocorticoid-sparing effect of
mepolizumab in eosinophilic asthma. N
Engl J Med. 2014 Sep 25;371(13):1189-
97.
18. Nair P, Wenzel S, Rabe KF, et al. Oral
glucocorticoid-sparing effect of benrali-
zumab in severe asthma. N Engl J Med.
2017 Jun 22;376(25):2448-58.
19. Rabe KF, Nair P, Brusselle G, et al. Ef-
ficacy and safety of dupilumab in glu-
cocorticoid-dependent severe asthma. N
Engl J Med. 2018 Jun 28;378(26):2475-
85.
20. Boulet L-P, Godbout K. Oral corti-
costeroids tapering in severe asthma.
